Home » Topics » BioWorld Science

BioWorld Science
RSS

CTA approved in Vietnam for phase I/II/III study of SARS-CoV-2 vaccine ARCT-154

Aug. 3, 2021

Phase I data with ANG-3070 pave way for phase II study in primary proteinuric kidney diseases

Aug. 3, 2021

Phase I trial evaluates iPSC-derived CAR T-cell therapy FT-819 for CD19+ malignancies

Aug. 3, 2021

ST-067 enters first-in-human study in relapsed or refractory solid tumors

Aug. 3, 2021

Intranasal vaccination with ChAdOx1 nCoV-19 reduces viral shedding in preclinical models

Aug. 3, 2021

Abcentra studies orticumab in subjects with psoriasis and cardiometabolic risk factors

Aug. 3, 2021

Collagenase clostridium histolyticum improves foot function in plantar fibromatosis study

Aug. 3, 2021

China's NMPA approves INDs for IASO's CD19/CD22 CAR-T therapy

Aug. 3, 2021

Gem gene sparkles as ischemic stroke drug discovery target

Aug. 3, 2021

Phase II data show safety and efficacy of OCS-02 in dry eye disease

Aug. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...